Eli Lilly slashes Zepbound to £227 ($299) monthly for US cash payers, but just £31 ($41) in India – though £241 ($319) in Japan.

Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Calls have been more popular than usual in the options pits. LLY's 50-day call/put volume ratio of 2.23 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX ...

Eli Lilly has cut cash prices for its weight-loss drug Zepbound on LillyDirect, lowering monthly costs to $299–$449. The move ...

Eli Lilly and Company (LLY) is a global pharmaceutical leader focused on discovering, developing, and commercializing ...

Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and ...

With no evidence base to draw upon, clinicians are sharing strategies to help patients stop taking the new weight-loss drugs ...

New guidelines from the World Health Organization (WHO) recommend using GLP-1 medications to help manage obesity along with a ...

The cross-asset backdrop is classic late-cycle: softer yields, a weaker dollar and bifurcated risk appetite. The U.S. Dollar Index (DXY) dropped roughly 0.6% to around 98.24, its lowest reading since ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.